Aurora Cannabis Inc. vs Merck & Company, Inc. — Stock Comparison

ACB
Aurora Cannabis Inc.
$3.48
▲ 1.16%
vs
MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
Q·Score Winner
Merck & Company, Inc.
MRK6.7/10vs 4.8/10

Q·Score Breakdown

4.8
Bearish
Overall
6.7
Neutral
2.2
Quality
6.2
8.2
Health
7
2.4
Growth
6.2
6.3
Valuation
7.2
5.6
Sentiment
7.1
ACB

Clean balance sheet with low leverage (0.2× debt-to-equity).

currently unprofitable (-23% margin).

MRK

Forward P/E of 11.5× is low relative to sector peers.

Analyst Consensus

BUY
Target $6.42 (+84.5%)
1 analysts
BUY
Target $129.74 (+15.7%)
27 analysts

Fundamentals

ACB
MRK
Trailing P/E
31.5×
-31.6×
Forward P/E
11.5×
-22.5%
Profit Margin
13.6%
36.0%
Gross Margin
76.6%
-15.5%
ROE
6.8%
Revenue Growth
4.9%
-94.7%
Earnings Growth
1.32
Beta
0.28
Price / Book
$206M
Market Cap
$277.0B
$3 – $7
52-Week Range
$73 – $125

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →